Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04459598 · ClinicalTrials.gov registry record · Phase 1
A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants
A Phase 1 study, sponsored by Daiichi Sankyo Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT04459598 is a Phase 1 study that has completed, run by Daiichi Sankyo Co.. The registered enrollment target is 32 participants.
The verdict
NCT04459598, a Phase 1 study, has completed, sponsored by Daiichi Sankyo Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This drug-drug interaction (DDI) study has been designed to investigate the effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of quizartinib and its major circulating active metabolite AC886.
Interventions
- DRUG Quizartinib
- DRUG Efavirenz
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-08-19 |
| Est. Completion | 2020-10-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04459598
The ClinicalTrials.gov registry entry for NCT04459598 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo Co., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Quizartinib is the first listed.
NCT04459598 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04459598 about?
NCT04459598 is a clinical study titled "A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants". This drug-drug interaction (DDI) study has been designed to investigate the effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of quizartinib and its major circulating active metabolite AC886.
What is the current status of trial NCT04459598?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2020-08-19. Estimated completion is 2020-10-14.
What interventions are being tested in trial NCT04459598?
The interventions under investigation include: Quizartinib (DRUG), Efavirenz (DRUG).
Who is sponsoring clinical trial NCT04459598?
This trial is sponsored by Daiichi Sankyo Co., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.